The FDA has granted breakthrough therapy designation Trodelvy for adults with extensive-stage small cell lung cancer who ...

Gilead Sciences has been a relatively solid performer this year in the biotech sector as its peers have struggled. The stock is up nearly 15% year-to-date, lagging the S&P 500. Yet it's rebounded 35% ...

Biotech giant Gilead Sciences, Inc. GILD has put up a steady performance in 2024 amid a volatile market. Its shares have ...

Our top content for the year highlight many challenges the field of non–small cell lung cancer (NSCLC) encountered, with data ...

Gilead Sciences, Inc. has announced that Trodelvy (sacituzumab govitecan-hziy) has received Breakthrough Therapy Designation ...

Assembly Biosciences (ASMB) announced an equity investment of $20.1M by Gilead Sciences (GILD) to purchase additional Assembly Bio common stock and an amendment to their collaboration to advance the ...

Gilead announces that the FDA grants a second Breakthrough Therapy designation to Trodelvy for the extensive-stage small cell ...

In September 2024, Gilead announced a strategic partnership with Genesis Therapeutics, focusing on AI to discover and develop ...

A Phase 2 study showed encouraging results with Trodelvy as a second-line treatment for extensive-stage small cell lung ...

Investors are bullish on Gilead as the stock surges on successful launches and strong financial health, offering potential ...

The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Trodelvy (sacituzumab ...